凋亡抑制因子Survivin的研究进展
被引量:6
摘要
Survivin是凋亡抑制因子家族的新成员,是迄今发现的最强大的凋亡抑制因子。Survivin兼有调节细胞周期和抑制细胞凋亡的双重作用,对细胞存活至关重要;Survivin在正常组织和肿瘤组织中的差异性表达,能准确反映肿瘤分级、淋巴转移、放化疗的疗效、复发倾向及预后。
出处
《山东医药》
CAS
2014年第21期100-101,共2页
Shandong Medical Journal
参考文献19
-
1Li F, Ling X. Survivin study: An update of " What is the next wave" [J]. Cellular Physiol, 2006,208(3) :476-486.
-
2Chantalat L, Skoufias DA, Kleman JP, et al. Crystal structure of human surviving reveals a bow tie-shaped dimer with two unusual alpha-helical extensions [ J ]. Mol Cell, 2000,6 ( 1 ) : 183-189.
-
3Yamamoto T, Tanigawa N. The role of survivin as a new target of di- agnosis and treatment in human cancer[ J]. Med Electron Microsc, 2001,34(4) :207-212.
-
4Smith SD, Wheeler MA, Plescia J, et al. Urine detection of survi- ving and diagnosis of bladder cancer[ J]. JAMA, 2001,285 (3) : 324-328.
-
5Altieri DC. Survivin, versatile modulation of cell division and ap- optosis in cancer[J]. Oncogene, 2003,22(53) :8581-8589.
-
6LaCasse EC, Baird S, Korneluk RG, et al. The inhibitors of apop- tosis(IAPs) and their emerging role in cancer[J]. Oneogene, 1998,17 (25) : 3247-3259.
-
7Marusawa H, Matsuzawa S, Welsh K, et al. HBXIP functions as a cofactor of surviving in apoptosis suppression [ J ]. EMBO, 2003, 22( 11 ) :2729-2740.
-
8Dohi T, Okada K, Xia F, et al. An IAP-IAP complex inhibits ap- optosis [ J ]. J Biol Chem, 2004,279 ( 33 ) : 34087-34090.
-
9Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by surviving [ J ]. Nature, 1998,396 ( 6711 ) : 580-584.
-
10Ahieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy[J]. Trends Mol Med, 2001,7(12) : 542-547.
二级参考文献26
-
1Karatzas T,Vasileiadis I,Kapetanakis S. Risk factors contributing to the difference in prognosis for papillary versus micropapillary thyroid carcinoma[J].{H}AMERICAN JOURNAL OF SURGERY,2013.
-
2Ranjbari N,Rahim F. The Ki-67/MIB-1 index level and recurrence of papillary thyroid carcinoma[J].{H}Medical Hypotheses,2013,(3):311-314.
-
3Chung YJ,Lee JS,Park SY. Histomorphological factors in the risk prediction of lymph node metastasis in papillary thyroid carcinoma[J].{H}HISTOPATHOLOGY,2013,(4):578-588.
-
4Wu LS,Milan SA. Management of microcarcinomas (papillary and medullary) of the thyroid[J].{H}Current Opinion in Oncology,2013,(1):27-32.
-
5Kim YA,Chang M,Park YJ. Detection of survivin and COX-2 in thyroid carcinoma:anaplastic carcinoma shows overexpression of nuclear survivin and low COX-2expression[J].KoreanJPathol,2012,(1):5560.
-
6MakkiFM,Taylor SM,Shahnavaz A. Serum biomarkers of papillary thyroid cancer[J].J Otolaryngol Head NeckSurg,2013,(1):16-25.
-
7Yousaf U,Christensen LH,Rasmussen AK. Immunohistochemical staining for thyroid peroxidase (TPO) of needle core biopsies in the diagnosis of scintigraphically cold thyroid nodules[J].{H}Clinical Endocrinology(Oxford),2008,(6):996-1001.
-
8Necochea-CampionRD,Chen CS,Mirshahidi S. Clinico-pathologic relevance of Survivin splice variant expression in cancer[J].{H}CANCER LETTERS,2013.
-
9G(o)rgün D,Se(c)ik F,Midilli K. Diagnostic and prognostic significance of survivin levels in malignant pleural effusion[J].{H}Respiratory Medicine,2013,(8):1260-1265.
-
10Chen Z,Liu N,Zhu G. Targeting of the antiapoptotic gene survivin in human thyroid carcinoma[J].Int J MolMed,2012,(3):465-472.
共引文献9
-
1魏卓文,党冬梅.胃癌组织中p16、Cyclin D1和Survivin的表达及其相关性[J].延安大学学报(医学科学版),2014,12(2):15-17. 被引量:1
-
2刘卫国.Survivin、BRAF、Notch1在甲状腺良恶性肿瘤中的差异表达及其与血清指标的关系[J].海南医学院学报,2015,21(2):250-252. 被引量:7
-
3艾秀清,张银华,司马义力.买买提尼亚孜,木妮热.木沙江.晚期乳腺癌患者Survivin的表达情况及与放疗敏感性的关系[J].中国实验诊断学,2015,19(6):912-915. 被引量:5
-
4钱金锋,杨其昌,谢慧君,张晓娟,沈屹,高翠玉.CyclinD1和Survivin在乳腺浸润性导管癌组织中的表达及意义[J].现代中西医结合杂志,2016,25(11):1151-1154. 被引量:5
-
5赵倩,杨亮,朱丽萍.Galectin-3、Caspase-3在乳腺癌组织中的表达和临床病理学意义[J].新疆医科大学学报,2016,39(10):1294-1298. 被引量:2
-
6董超,徐正丰,邱涵,余敏.Galectin-9在乳腺癌组织中的表达及其对癌细胞侵袭转移的影响[J].山东医药,2016,56(41):81-83. 被引量:7
-
7艾秀清,董晓霞,张银华,木妮热.木沙江.乳腺癌术后局部复发患者癌组织中Survivin、MMP-9的表达变化及意义[J].山东医药,2017,57(25):20-22. 被引量:8
-
8李伟,李永红,江晖.survivin和MCM7在甲状腺乳头状癌组织中的表达及其与患者临床特征的关系[J].癌症进展,2019,17(17):2055-2058. 被引量:3
-
9朱春良,帅剑波,邵庆庆,胡广明.探讨抗体标记物MC联合应用CK19,TPO,Galectin-3,KI-67在甲状腺乳头状病变中应用[J].世界最新医学信息文摘,2015,15(53):11-12.
同被引文献59
-
1江斌,菅志远,兰明银,严斌,曾少波.Survivin在胆囊癌组织中的表达及与病理的关系[J].中华实验外科杂志,2004,21(10):1204-1205. 被引量:5
-
2Hai-GangLi,De-RongXie,Xi-MingShen,Hong-HaoLi,HongZeng,Yun-JieZeng.Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma[J].World Journal of Gastroenterology,2005,11(10):1445-1451. 被引量:38
-
3万云乐,丁伟,郑树森,闵军,王捷.原发性胆囊癌Survivin和Ki-67的表达及意义[J].中华实验外科杂志,2006,23(8):919-921. 被引量:17
-
4鲜军舫,王振常,罗德红,等.头颈部影像学诊断必读[M].北京:人民军医出版社,2007:197-199.
-
5Davis TW, O'Neal JM,Pagel MD,et al. Synergy between celecoxib and radiotherapy results from inhibition of cy- clooxygenase-2-derived prostaglandin E2,a survival fac- tor for tumor and associated vasculature[J]. Cancer Res, 2004,64( 1 ) : 279-285.
-
6Milas k Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy: Preclinical basis[J]. Am J Clin 0neol,2003, 26(4) :66-69.
-
7Bai XM ,Jiang H, Ding JX, et al. Prostaglandin E2 upreg- ulates survivin expression via the EP1 receptor in hepa- tocellular carcinoma cells[J]. Life Sciences,2010, (86): 214-223.
-
8Adegbola O,Pasternack GM.Phosphorylated retinoblastoma protein complexes with pp32 and inhibits pp32-mediated apoptosis[J].J Biol Chem,2005,280(16):15497-15502.
-
9Xu C,Yamamoto-Ibusuki M,Yamamoto Y,et al.High survivin m RNA expression is a predictor of poor prognosis in breast cancer:a comparative study at the m RNA and protein level[J].Breast Cancer,2014,21(4):482-490.
-
10Antonatopoulou AG,Floratou K,Bravou V,et al.The survivin-31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival[J].Anal Cell Pathol(AMST),2010,33(5):177-189.
引证文献6
-
1李峰,叶向东,连学雄,冯宇鹏,廖耀军.CD147蛋白和凋亡抑制基因Survivin在膀胱癌中的表达及其相关性[J].现代泌尿生殖肿瘤杂志,2015,7(1):44-46. 被引量:2
-
2王阳,邹明雷,吕晶晶,付培彪.塞来昔布联合放疗对人胆管癌细胞凋亡的作用研究[J].中国现代医生,2015,53(10):19-21. 被引量:3
-
3黄延波,许文敏,洪泽华,林凯鸿,蔡佳,陈旭彬.血清Livin联合Survivin检测在视网膜母细胞瘤诊断的应用价值[J].中国医药科学,2016,6(11):144-146. 被引量:2
-
4张大海,吕国晓,马海锋,蔡忠芳,郭冬.塞来昔布放射增敏作用在食管癌放化疗中的临床应用研究[J].中国基层医药,2018,25(1):14-17. 被引量:2
-
5栗宏红,段吉明,薛军军,李文龙,赵舸.Survivin与胆囊癌的关系[J].临床医药实践,2018,27(5):382-384. 被引量:1
-
6濮忠建,杨爱珍,秦叔逵,许丹,陈惠英,徐海军,华海清.消癌平注射液联合奥沙利铂诱导肝癌HepG-2细胞凋亡及其相关机制的研究[J].湖北中医杂志,2020,42(1):3-6. 被引量:4
二级引证文献14
-
1梁彦,崔飞伦.尿生存素联合液基细胞学检测对膀胱癌的诊断价值[J].医学研究生学报,2016,29(11):1211-1213. 被引量:5
-
2徐刚,薛义军,邹晓峰,李龙滨,袁源湖,肖日海,邹毓华.调控CD147基因表达的MicroRNA分子鉴定及其抗膀胱癌转移研究[J].中国现代医生,2016,54(29):1-3. 被引量:1
-
3李丽萍,余志高,李小菊,鲁文静.塞来昔布对非小细胞肺癌放疗的增敏作用[J].解放军医药杂志,2017,29(1):40-42. 被引量:5
-
4郝兴,刘建生,陈博艺,张宝明.选择性环氧合酶-2抑制剂塞来昔布抗肿瘤作用机制的研究进展[J].中国现代医生,2016,54(34):157-160. 被引量:7
-
5刘元真.眼动脉介入化疗对眼内晚期视网膜母细胞瘤的临床疗效观察[J].实用癌症杂志,2017,32(8):1247-1250. 被引量:3
-
6佐志刚,蔡晓军,汤继英.康力欣胶囊放射增敏作用在食管癌放化疗中的临床应用效果分析[J].中外医疗,2020,39(10):88-90.
-
7李倩,董媛,石妍,张春霞,常虹,白万富,董志强,石松利.奥沙利铂联合用药的临床应用与用药安全[J].包头医学院学报,2020(4):117-121. 被引量:2
-
8黄柳燕,熊新为,梁梦露,戴伶伶.依托考昔与塞来昔布治疗类风湿关节炎的效果及不良反应比较[J].中国基层医药,2020,27(18):2272-2274. 被引量:8
-
9邓姿峰,罗瑜琳,汤文权.Livin基因沉默对视网膜母细胞瘤细胞侵袭性的影响及其机制研究[J].眼科新进展,2020,40(12):1130-1134. 被引量:1
-
10田野,唐子滨,向海兵.基因干扰CXCL4对GBC-SD细胞恶性增殖和上皮间质转化的影响[J].医学分子生物学杂志,2021,18(2):104-109. 被引量:2
-
1史立军,闫彬彬,李双星,孟艳玲,马珊珊,刘铁夫,李呼伦.As_2O_3对胰腺癌细胞株的抑制作用及其机制的初步探讨[J].中国病理生理杂志,2005,21(8):1572-1574. 被引量:6
-
2程平,秦蓉,张红,吴继锋,王道斌.凋亡抑制因子Survivin和Livin在胃癌中的表达及意义[J].世界华人消化杂志,2008,16(8):850-855. 被引量:13
-
3郑清友,靳风烁,李增鹏,杨雨馨,刘光,黄晓楠.凋亡抑制因子survivin在膀胱移行细胞癌中的表达及意义[J].第三军医大学学报,2005,27(10):1030-1032. 被引量:8
-
4唐薇薇,郑洪,王琳琳,厉国慧,岳昌武,姚宁.凋亡抑制因子Survivin siRNA荧光表达载体的构建[J].遵义医学院学报,2008,31(6):565-567. 被引量:1
-
5王永俊,施小六,汤建光,胡治平,薛志刚,夏昆.RNAi下调survivin表达诱导成人神经细胞瘤细胞凋亡[J].基础医学与临床,2006,26(7):745-750. 被引量:6
-
6李际春,何玲.卵巢癌组织中Survivin的表达及其临床意义[J].宁夏医学杂志,2008,30(1):41-43. 被引量:1
-
7齐世美,毕富勇.Survivin与bcl-2相关性研究进展[J].皖南医学院学报,2006,25(1):71-73. 被引量:5
-
8孙裕昌,沈娟,沈晗,邵红伟,黄树林.Hela细胞Survivin克隆及HLA-A2限制性CTL表位预测研究[J].中国免疫学杂志,2007,23(11):1044-1047. 被引量:2
-
9丁丽红,吴文清,曹立宇,潘美华,张洪福.Survivin与VEGF及其受体FLT-1在结直肠癌中的表达及其临床意义[J].安徽医科大学学报,2008,43(6):634-637. 被引量:9
-
10王亮,陈昭颉,王庆堂,曹文峰,简燚,刘祥丹,汪俊超.低氧诱导因子1α在膀胱移行细胞癌中表达及其临床意义[J].四川医学,2005,26(7):762-763.